Receive The Newest Study Notifications

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County. City of Hope is a world-renowned...

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with...

Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the opening of a pharmacologic study of the ability of its lead clinical compound, LB-100, to enter the brain and penetrate recurrent glioblastoma multiforme tumors in patients in which surgical removal of...

American scientists started the clinical trial of a universal influenza vaccine candidate for its safety and ability to induce an immune response in healthy volunteers. The researchers at the National Institute of Allergy and Infectious Diseases (NIAID), under the...

Durable improvement in best-corrected visual acuity (BCVA), as GS010-treated eyes sustain +15.4 ETDRS letters equivalent improvement versus baseline and +28.1 ETDRS letters equivalent versus nadir Bilateral improvement continues in key visual functions BCVA and...

d today that it has filed with the U.S. Food and Drug Administration (FDA) the pivotal trial protocol for leronlimab as a monotherapy for HIV patients. The latest investigative monotherapy trial for HIV has now produced sufficient data for the Company’s Key Opinion...

George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors. The development will...

EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today its plans to take the next steps to initiate Phase III...

Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV,...

Icon Launches New Clinical Trial Patient Engagement Platform Platform designed to Increase visibility of potential study participants to sites and sponsors May 14, 2019 — Icon plc announced the release of its web-based clinical trial patient engagement platform, to...

Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today that the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has...

NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it will initiate the Phase I clinical trial of its Stelara®(ustekinumab) biosimilar in the second...

Ping An Insurance (Group) Company of China, Ltd. ("China Ping An", "Ping An", the "Group" or the "Company"; stock codes: HKEX 2318 and SSE 601318) is pleased to announce that its technology arm, Ping An Technology, has completed a prospective multi-center clinical...

Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce the completion of its clinical trial on its lead cannabis treatment (“CTL-X”) for acute pain. The clinical...

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the initiation of the Phase 2 portion of a global, open-label, randomized clinical trial studying the...

The recent strong funding support for Alzheimer’s science at NIA is a wonderful opportunity. But this exciting surge in clinical research brings with it a burgeoning demand for clinical research volunteers, and NIA is eager to assist investigators in achieving their...

-- Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1 --  Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that the company has achieved target enrollment of...

A new clinical trial at The Ohio State University Wexner Medical Centerand two other sites is testing an innovative procedure that may provide hope in the fight against Alzheimer’s disease. The non-invasive procedure uses low-intensity focused ultrasound to open the...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical trial evaluating ABO-101, its novel...

A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed or refractory multiple myeloma. The study,...